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The study of gene products that were initially found associated with cellular
transformation (fos, myc, p53) has provided insight into the sequence of events
accompanying initiation and maintenance of normal cell growth (1-4). In addi-
tion, the study of proteins that were originally found involved in growth regu-
lation of normal cells has contributed to the understanding of malignant
transformation (5-10). Transformation-induced overexpression and growth-
controlled expression in normal cells, therefore, are two characteristic proper-
ties of molecules that are critically involved in promotion of cell proliferation.
To identify cell surface molecules that might play an important role in cell
growth, we have used these characteristics to test a large number of human cell
surface antigens defined by mAbs. Emphasis was placed on antibodies that
reacted preferentially with human tumors or tumor cell lines. Over 150 mAbs
previously developed in our laboratory were examined (11-22, and unpublished
observations), and one group of antibodies (11, 12) that detects a 130-kD cell
surface glycoprotein (gp130) was selected for detailed study.
We have found that gp130 is overexpressed on the cell surface of both virally
and chemically transformed fibroblasts, fibrosarcoma cell lines, a cell line
derived from a squamous cell carcinoma of the skin, and T cell leukemia cell
lines, in comparison to their normal counterparts. Furthermore, gp130 is
growth regulated in human diploid fibroblasts and T cells. These properties indi-
cate that gp130 fits the model of a molecule relevant to cell proliferation. Other
cell surface glycoproteins that reveal a similar regulatory pattern in the normal
and transformed state have been identified as the receptors for transferrin
(gp92) and IL-2 (gp55) (23-25). Our results raise the possibility that gp130 is a
cell surface receptor for an as yet unidentified growth-promoting agent.
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Materials and Methods
Cells and Culture Conditions.
￿
Human cell lines and short term cultures were grown in
RPMI 1640 supplemented with 2mM glutamine, 146 nonessential amino acids, 100 U/
ml penicillin and 100 U/ml streptomycin. Primary cultures of normal keratinocytes were
established and maintained in MEM as previously described (26). Tissue culture medium
contained 1046 FCS. Cell lines SV/HF-4, SV/HF-5, SV/HF-5/89 and SV/HF-tsA were
derived from the diploid bone marrow fibroblast cell line Hs74 after transformation with
SV40 (27). The fibroblast cell line KD was established from a lip biopsy of an 18-year-
old healthy male. This line (28) and its chemically transformed derivatives (HUT 12 and
HUT 14, reference 28) were provided by J. Leavitt, Linus Pauling Institute (Palo Alto,
CA). The fibrosarcoma cell line 8887 was provided by S. Aaronson, National Institutes
of Health (Bethesda, MD). Adult fibroblast cultures (n - 8) were derived from fresh
surgical specimens of lung, skin, or various other tissues. The fibrosarcoma cell line HT
1080 was obtained from the American Tissue Type Culture Collection (ATCC, Rockville,
MD), and the fibrosarcoma cell line SW 684, and normal fibroblast lines from fetal skin,
F135-60-86 and F135-60-18, were obtained from the cell bank at Memorial Sloan-Ket-
tering Cancer Center. Cell line SCLI, derived from a facial squamous cell carcinoma,
was provided by N. E. Fusenig, Deutsches Krebsforschungszentrum (Heidelberg, Federal
Republic of Germany). Five cytolytic T cell clones (NBL 4, 11, 46, 56, 99) in long-term
culture (>2 mo) were provided by N. Flomenberg, Memorial Sloan-Kettering Cancer
Center.
Monoclonal Antibodies. The following mAbs were used: mAbs recognizing gpl30 :
Q14, 846, N9, R23 (references 11, 12); control mAbs recognizing unrelated cell surface
glycoproteins: AJ2 (14), T16 (13), CNT10 (M. Jennings, unpublished data); mAbs for T
cell purification: B-1 and B-4 (B cells), MY-4 and MY-8 (monocytes, granulocytes), MO-
1 (monocytes) provided by J. Griffin, Harvard Medical School (Boston, MA), and H-25
(NK cells, some monocytes) provided by R. Knowles, Memorial Sloan-Kettering Cancer
Center; mAbs inducing T cell activation: OKT3 (CD3, Ortho Pharmaceutical, Raritan,
NJ) and 9 .1 (CD2), 9.6 (CD2), SP34 (CD3) provided by S. Yang, Memorial Sloan-Ketter-
ing Cancer Center; mAbs confirming T cell activation: OKT9 (Ortho Pharmaceutical)
recognizing the transferrin receptor, L243 (ATCC) recognizing a monomorphic epitope
of human class II glycoproteins.
Rosetting Assays.
￿
Rosetting assays for the detection of cell surface antigens on cul-
tured cells were performed according to methods previously described (14, 29).
Immunofluorescence .
￿
Adherent cells were detached using 2 mM EDTA or 0 .0546 Tryp-
sin/0.0246 EDTA in PBS. Short term trypsin treatment (3-4 min) at room temperature
did not affect gp130 expression. Cells were suspended in RPMI 1640 containing 1046
FCS and incubated with saturating amounts of mAb for 45 min at 4°C. Control samples
were incubated with purified mouse IgG (Coulter Immunology, Hialeah, FL) or with a
mouse mAb detecting an unrelated cell surface antigen (T16, CNT10) that was not
expressed on the cell types studied. After two washes with PBS, FITC-conjugated F(ab)2
fragments of goat anti-mouse IgG (Cappel Laboratories, Cochranville, PA) were added
for 45 min at 4°C. After three final washes in PBS, the cell preparation was analyzed
using a fluorescence microscope or a FACS, or was further processed for bivariate anal-
ysis of DNA content vs. cell surface immunofluorescence.
Radioimmunoprecipitation.
￿
Cells were metabolically labeled with [saS]methionine (60-
200 gCi/ml; New England Nuclear, Boston, MA) for 12 h. A long labeling period was
used to maximize the possibility that steady-state conditions were examined. Glycopro-
teins were isolated from NP-40-solubilized cell extracts by adsorption to Con A (Phar-
macia Inc., Uppsala, Sweden) (30). Immunoprecipitation was carried out as previously
described (14). Briefly, samples of the Con A-bound fraction (1 .5 X 106 cpm) were
incubated with 1-2 pl of serum or ascites containing mAb for 2 h at 4°C. Immune com-
plexes were then precipitated with protein A-Sepharose CL-4B (Pharmacia, Inc.) prein-
cubated with rabbit anti-mouse Ig (Dako Corp., Santa Barbara, CA). After 10 washes
with buffer (0 .546 NP-40, 0.146 SDS, 0 .15 M sodium chloride, and 0 .01 M Tris, pH 7.5),1686
￿
A TRANSFORMATION-ASSOCIATED CELL SURFACE GLYCOPROTEIN
precipitated glycoproteins were processed by SDS-PAGE on 7.5% or 9% polyacrylamide
gels. For fluorography, gels were immersed in 0.5 M sodium salicylate for 20 min . To
compare glycoprotein synthesis of different cell cultures, equal numbers of counts of the
Con A-bound fractions were immunoprecipitated. The amounts of precipitated glyco-
proteins were determined by quantitative density scanning of the fluorographs.
DNA Fluorescence.
￿
Cells processed for immunofluorescence analysis of surface glyco-
proteins were stained with propidium iodide (PI)' (Sigma Chemical Co., St. Louis, MO)
(31). Aliquots of a stock solution of 250 jug/ml PI and 5% (vol/vol) Triton-X-100 in H2O
were added to the cell suspension (106 cells/ml) to reach final PI and detergent concen-
trations of 50 Ag/ml and 1%, respectively. In addition, cells were treated with 1,000 U
of high specific activity RNase per milliliter of cell suspension (RASE; Worthington Bio-
chemical Corp, Warrington, PA). After a 20-min incubation at room temperature, sam-
ples were analyzed in a flow cytometer.
Bivariate Analysis of DNA vs. Immunofluorescence.
￿
The integrated values of PI red flu-
orescence, FITC-green fluorescence, and the duration of the red fluorescence pulse
were recorded in list mode for each cell using a System 50H flow cytometer (Ortho Diag-
nostic Systems, Inc., Westwood, MA) interfaced to an Ortho 2150 data analysis system.
The duration of the red fluorescence pulse (pulse width) of each cell was used to elimi-
nate doublets (32). Linear and log fluorescence values for cellular DNA and immunoflu-
orescence, respectively, were recorded for 104 cells. Interactive data analysis provided
the mean fluorescence values of cells as well as single parameter frequency distribution
histograms and bivariate displays of cellular DNA vs. log FITC fluorescence.
Preparation of T Lymphocytes.
￿
Peripheral blood mononuclear cells were separated from
heparinized whole blood of healthy volunteers by sedimentation on a Ficoll-Hypaque
density cushion (density 1 .077 gm/cms, Pharmacia Fine Chemicals, Piscataway, NJ). After
removal of monocytes by adherence to plastic petri dishes (45 min, 37°C), T cells were
purified by negative selection using an indirect panning technique (33). Lymphocytes
were incubated simultaneously with saturating amounts of mAbs B-1, B-4, MY-4, MY-8,
H-25, MO-1, and N901 for 30 min at 4°C, washed twice, and resuspended in RPMI -f-
10% FCS. 4 ml of the cell suspension (5 X 106 cells/ml) were then dispensed into one
100-mm plastic dish (No. 1005, Falcon Labware, Oxnard, CA) precoated with 5 ml of
affinity-purified goat anti-mouse Ig (20 Ag/ml PBS, overnight at 4°C) (Boehringer-Mann-
heim Biochemicals, Indianapolis, IN). Cells were incubated at 4°C for 90 min on the
dishes. The nonattached T lymphocytes were collected by swirling the plates and decant-
ing the supernatant, followed by four gentle washes of the plates with media. Collected
cells were washed twice with medium before further testing.
Activation of T Lymphocytes.
￿
T lymphocytes (98% CD3+ cells, 0.5 X 106 cells/ml) were
incubated in MLC for 5 d, or with mAbs: (a) OKT3 (ATCC clone ascites 1 :1,000 vol/
Vol) for 16 h or 3-4 d; (b) 9.1 and 9.6 combined (1 Ag/ml each), detecting the internal
and external domain of the CD2 molecule, respectively, for 8 h or 3 d (S . Yang et al.,
manuscript in preparation) ; (c) 9 .1 and SP34 combined (20 g/ml each), detecting the
CD2 and CD3 molecule, respectively, for 3 d (34). T cell activation was confirmed by
[';H]thymidine uptake or by induction of transferrin receptor (mAb OKT9) and HLA-
DR (mAb L243) expression, using flow cytometry.
Results
Strong Cell Surface Expression of a 13041) Glycoprotein (gp130) Is Induced in
Human Fibroblasts after Viral and Chemical Transformation. To determine
whether the expression of a given cell surface antigen changes after malignant
transformation, we compared the two human fibroblast cell lines Hs 74 and KD
and their virally (SV/HF-5, SV/HF-5/39) or chemically (HUT 12, HUT 14)
Abbreviations used in this paper: HU, hydroxyurea; PI, propidium iodide; TR, transferrin
receptor.KLEIN ET AL .
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transformed counterparts . Cell line SV/HF-5, which gave rise to line SV/HF-5/
39, was derived from a soft agar colony after Ca-phosphate-mediated transfec-
tion of origin-defective SV-40 DNA into Hs 74 cells (27, 35) . The other two
transformed cell lines (HUT 12, HUT 14) were isolated from separate foci of
KD fibroblasts after treatment with 4-nitroquinoline oxide (28) . Although
screening with the panel of mAbs identified several cell surface antigens that
showed increased expression on transformed fibroblasts, changes in gp130
expression were particularly striking . Four mAbs defining four distinct epitopes
on gp130 were used, and these antibodies gave parallel results in rosetting,
FACS, and immunoprecipitation analysis, indicating detection of a single gp130
species. In subsequent experiments mAbQ14 was used .
Fig. 1 shows a comparison of gp130 expression by the normal fibroblast line
Hs 74 and its SV40-transformed derivative, SV/HF-5/39 . Surface expression of
gp130 was highly increased on SV/HF-5/39 cells under optimal conditions for
cell growth of both lines, i.e ., intermediate cell density in medium supplemented
with 10% FCS. Synthesis of gpl30, as determined by metabolic labeling, was
similarly increased in the transformed line (Fig . 2) . The level of radiolabeled
gp130 was 15-20-fold higher in SV/HF-5/39 cells as compared with Hs 74 cells.
The two chemically transformed lines, HUT 12 and HUT 14, also showed high
levels of gp130; synthesis of gp130 was not detectable in the parent line under
comparable conditions . These results indicate that induction of gp130 expres-
sion in transformed fibroblasts is not dependent on a particular transforming
agent . Further studies showed that induction of gp130 expression was an early
consequence of Hs 74 transformation . Three independent SV40-transformed
derivatives of the Hs 74 line (SV/HF-4, SV/HF-5, and SV/HF-tsA) showed
increased gp130 expression at an early passage (passage 2-10) after isolation, as
shown in Fig . 3 for SV/HF-5 cells . These cell lines had been isolated under dif-
ferent selection conditions after transfection with diverse constructs of wild-type
(27) and tsA 58 origin-defective (Radna, R., and H . Ozer, unpublished results)
SV40 genomes . In addition, the three human fibrosarcoma cell lines (HT 1080,
FIGURE 1 . Surface expression of gp130 on
normal and transformed human fibroblasts as
analyzed by flow cytometry. Cells were incu-
bated with mAbQ14 (gp130) or mAbTI6
(control) . Cell lines : Hs 74 (normal fetal fibro-
blast), LF-2 (normal adult fibroblast), SV/HF-
5/39 (SV40-transformed Hs 74), HT 1080
(fibrosarcoma cell line) .1688
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FIGURE 2 . gp130 synthesis in normal and transformed
fibroblasts . Con A-bound fractions of NP-40 cell lysates
from [96S]methionine-labeled parallel cultures (Hs 74 and
SV/HF-5/89 ; KD and HUT 14, respectively) were analyzed
by immunoprecipitation and SDS-PAGE . The fluorogram
shows immunoprecipitates obtained with different mAbs :
(lane 1) AJ2 (gp210/170/140/30, constitutively expressed
on all cell types, not transformation related) ; (lane 2) T16
(gp40-50, not expressed on fibroblasts) ; (lane 3) Q14
(gp130) ; (lane 4) OKT9 (gp92, TR) .
SW 684, 8387) expressed high levels of gpl30 on the cell surface, indicating
that in vivo transformation is also frequently associated with increased expres-
sion of gp130 (Fig . 1) . The 14 normal fibroblast cell lines tested, including Hs
74 and KD, showed significantly lower cell surface expression of gp130 than
transformed fibroblasts, with adult fibroblasts being consistently lower than fetal
fibroblasts (Fig . 1) .
Cell Surface Expression and Synthesis of gp130 Is Growth Regulated in Normal
Fetal Fibroblasts . Normal fibroblast lines derived from fetal skin (F135-60-86,
F135-60-18) were studied at an early passage under various growth conditions .
FIGURE 3 .
￿
Increased gp130 synthesis after in vitro transfor-
mation. Normal Hs 74 fibroblasts were compared with SV40-
transformed Hs 74 fibroblasts at an early stage after isolation
(SV/HF-5), and at a later stage after immortalization (SV/HF-
5/39) . Con A-bound fractions of ["S]methionine-labeled cul-
tures were prepared as described . Immunoprecipitates were
obtained with mAbAJ2 (lane 1), mAbT16 (lane 2), and
mAbQ14 (lane 3) . See Fig. 2 for mAb characteristics .KLEIN ET AL.
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Growing cultures were first incubated in medium containing a low concentra-
tion of serum (0.5% FCS) . After 4 d of serum starvation, cultures were stimu-
lated for 3 d with 20% FCS alone, or with 20% FCS and 1 .5 mM hydroxurea
(HU) . Parallel cultures were maintained at low serum concentration . Immuno-
precipitation of [3"S]methionine-labeled cultures showed that gp130 synthesis
was very low in serum-starved cells and significantly higher in serum-stimulated
cultures (Fig. 4) . In cultures growing in 20% FCS and 1 .5 mM HU, synthesis of
gp130 was even higher than in cultures growing in 20% FCS alone. We then
examined gp130 expression at different stages of the cell cycle . Bivariate analysis
ofDNA and cell surface immunofluorescence was performed on cultures main-
tained in the same way as those used for immunoprecipitation tests . In serum-
stimulated cultures (20% FCS), the mean fluorescence intensity of gp130 was
3 .5 times higher than in serum-starved cultures (Fig. 5 C . Comparison of the
Go-G, cell populations demonstrated similar differences ; serum-stimulated Go-
G, cells revealed a 3.2 times higher expression of gp130 than Go-G, cells of
serum-starved cultures (Fig . 5 B) . As Go and G, cells cannot be distinguished on
the basis ofDNA content per cell, we cannot tell whether expression of gp130
increased after serum stimulation in Go cells or in the transition of G, cells ; it
remained increased in cycling cells, as indicated by high gp130 levels in S and
G2M cells (Fig . 5 B [II]) .
As expected, cultures stimulated with FCS for 3 d in the presence ofHU also
showed an increase in mean fluorescence intensity ofgpl30 . The level of gp130
was 6.4 times higher than in serum-starved cultures (Fig. 5 C) . Analysis forDNA
content revealed that cells in such cultures were predominantly arrested in S-
phase. Interestingly, S-phase cells of these cultures consistently showed higher
gpl30 expression than S-phase cells of cultures stimulated with FCS in the
absence ofHU .
gp130 Is Not Found on the Cell Surface of Normal Keratinocytes but Highly
Expressed in a Squamous Cell Carcinoma. To determine whether transformation-
induced expression of gpl30 occurs in other cell types, we studied normal and
transformed human keratinocytes (Fig . 6) . gp130 was not detected on epidermal
cells derived from fresh surgical skin specimens or on keratinocyte cultures (KC,
FIGURE 4 .
￿
Growth control of gp130 synthesis
in normal fetal fibroblasts. Cultures of fetal
skin fibroblasts (F1S5-60-86, passage 6) were
serum starved for 4 d (0.5% FCS) . Parallel cul-
tures were then serum stimulated with 20%
FCS or with 20% FCS and 1 .5 mM HU or
maintained in medium containing 0.5% FCS .
After60h the culture medium waschanged to
methionine-free medium containing 65 Ci/ml
[saS]methionine and corresponding amounts
of dialyzed FCS (0.5%, 20% + HU or 20%)
for 12 h . NP-40 cell lysates were then pro-
cessed for immunoprecipitation . The fluoro-
gram shows immunoprecipitates obtained with
mAbT16 (control, lane 1) ; mAbAJ2 (control,
lane 2) ; mAb Q14 (gp130, lane 3) mAbOKT9
(TR, lane 4) .1690
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FIGURE 5 .
￿
Cell surface expression of gpl30 is increased on serum-stimulated G-G, cells
and on S/G2M cells . Parallel cultures of fetal skin fibroblasts (F135-60-86) were treated as
described in Fig. 4 and processed for bivariate analysis of DNA content and cell surface
immunofluorescence (gp130 ; mAbQ14) . (A) DNA histograms . (B) Bivariate recording of
DNA content and gpl30 immunofluorescence. Note the shift of serum-stimulated G-G,
cells (II) to higher gpl30 fluorescence intensity as compared with the serum-starved G-G,
cells (1) . (C) Single-parameter histograms of gp130 immunofluorescence from whole cultures
I, 11, III ; the histogram with the noncontinuous line represents the three superimposed con-
trols (mAbT16) .
FIGURE 6 .
￿
Synthesis and expression of gp130 in normal keratinocytes and in a squamous
cell carcinoma line. Cultures of KC normal adult keratinocytes (14 d in culture) and the SCIA
squamous cell carcinoma line were processed for immunofluorescence by flow cytometry (left)
and for immunoprecipitation (right) . (Left) mAbQ14 (gpl30) and mAbCNT10 (control);
(Right) lane 1, mAbQ14, lane 2, mAbCNT10 .n = 14). In contrast, a cell line derived from a facial squamous cell carcinoma
(SCL-1) showed high expression of gpl30, as measured by immunofluorescence
tests (Fig. 6 A) and by immunoprecipitation after metabolic labeling (Fig. 6 B) .
gp130 Is Induced in Activated T Cells and Overexpressed in a T Cell Leukemia
Line. In indirect immunofluorescence tests using flow cytometry, gp130 was
not detectable on PBMC, highly purified peripheral blood T cells, or cord blood
cells. When T cells were stimulated in MLC or with mAbs reacting with the T
cell receptor (CD3) or the sheep red blood cell receptor (CD2), gp130 expres-
sion was induced at low to moderate levels (Table 1). Similar levels of gp130
were found on cloned IL-2-dependent T cell lines (Table I).
In tests on cultured T cell leukemias, gpl30 was detected on 4/6 cell lines
(Table I) . 100% of HUT 102 and CRF-CEM cells expressed gpl30 at high levels,
whereas only a small percentage of MOLT-4 cells showed weak gp130 expres-
sion. Cell surface expression of gpl30 on HUT 102 cells was at least five fold
higher than on fresh normal activated T cells or T cell lines. These results indi-
cate that transformation is associated with overexpression of gp130 in a subset
of T cell leukemias.
Comparison of gp130 and Transferrin Receptor Expression. The transferrin
receptor (TR) is a cell surface glycoprotein known to be involved in cell prolif-
TABLE I
Cell Surface Expression ofgp130 on Human T Cells
KLEIN ET AL.
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* Cell surface expression of gp130 was assessed by flow cytometry after
indirect immunofluorescence staining with mAbQ14. Expression ranged
from weak (+) to very strong (++++).
T cells
gp130
Strength
expression*
Positive cells
RestingTcells
Peripheral blood, n = 10 0
Cord blood, n = 2 0
ActivatedT cells
MLC, n = 2 + 6-8
mAb OKT3 (CD3), n = 3 ++ 8-70
mAb 9.1 (CD2), 9.6 (CD2), n = 3 ++ 15-60
mAb 9.1 (CD2), SP34 (CD3), n = 2 ++ 7-13
T cell clones
NBL 4 ++ 15
NBL 11 + 13
NBL 46 + 8
NBL 56 ++ 53
NBL 99 + 70
T cell leukemias
HUT 102 ++++ 100
CRF-CEM +++ 100
MT-1 ++ 50
MOLT-4 + 8
P12 - 0
Jurkat _ 01692
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eration (25) . It has been shown that TR is growth controlled in human T lym-
phocytes and that its induction is required for cell division (24) . High levels of
TR have been found in tissues and cell lines derived from many different types
of human cancer (23, 36). In comparing the patterns of TR and gpl30 expres-
sion, we found significant differences. First, the increase of gp130 synthesis
after in vitro transformation of fibroblasts was markedly higher (15-20-fold)
than the increase observed for TR synthesis (<2-fold, Fig. 2). Second, synthesis
of gp130 in normal fibroblasts was clearly modulated by the growth state of
normal fibroblasts, whereas this could not be demonstrated for TR (see Fig. 4) .
Third, in contrast to the low levels of gp130 detected in activated T cells and in
long-term cultures of cloned T cells, TR was synthesized at significantly higher
levels in these cells. Finally, gp130 was not detectable in a number of human
tumor cell lines expressing high levels of TR.
Discussion
Several oncogene products have been found overexpressed in transformed
cells and growth controlled in normal cells (1-4, 37-39) . In this study, we have
found that gp130 shares these two characteristics . gp130 is a plasma membrane
glycoprotein that can be detected with immunorosetting or immunofluorescence
assays on the surface of cultured cells. Pulse chase experiments have demon-
strated a 100-kD precursor protein (12). Furthermore, treatment of this pre-
cursor protein with endoglycosidase H resulted in an 80-kD polypeptide possibly
representing the primary translational product (12). In our experiments, gp130
was not detectable in immunoprecipitates of spent medium after culture of
[_3'S]methionine-labeled high expressor cell lines, suggesting that the glycopro-
tein is not secreted. The gene encoding gp130 has been assigned to chromo-
some IIg13-gter by serological analysis of mouse-human somatic cell hybrids
(40, 41).
Strong expression of gp130 was induced in fibroblasts by in vitro transfor-
mation with two transforming agents. In addition, high levels of gp130 were
found in human cancer cells of diverse types: fibrosarcomas, a squamous cell
carcinoma, and T cell leukemias. Normal cultured cells of the same lineage
showed low or no detectable expression of gp130. Furthermore, gp130 is known
to be highly expressed on the cell surface of tumor cell lines derived from many
other tissues including neuroblastomas, melanomas, astrocytomas and lung car-
cinomas (11, 21, our unpublished data). In tests on tissue sections with immu-
noperoxidase and immunofluorescence, gp130 was found to have a restricted
distribution in normal tissues (endothelial cells, sebacious glands, reference 21).
In the case of malignant melanoma, 36/62 tumors were strongly positive for
gp130 (21). gp130 was not detectable in skin melanocytes in tissue sections, but
is expressed by cultured melanocytes growing in the presence of phorbol ester
and cholera toxin.
In two distinct normal cell systems, human fibroblasts and T lymphocytes,
gpl30 expression was shown to be modulated by the growth state of normal
cells. Our data indicate that gp130 expression increases significantly in serum-
stimulated fetal fibroblasts in Go or G,, possibly associated with the transition
from Go to the G, phase of the cell cycle, and that it persists at these higherKLEIN ET AL.
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levels during the S- and G2 M-phase of the cycle. In HU-treated cultures, there
was growth arrest of fibroblasts in S-phase (under our culture conditions of sin-
gle exposure to HU over a 3-d period). Interestingly, expression of gp130 on
the surface of these HU-treated cells was higher than expression in S-phase cells
growing in the absence of the inhibitor, a finding that raises the possibility that
altered S-phase characteristics after cell transformation might lead to the
increase of gp130 expression in transformed cells. On the other hand, gp130
may be constitutively overexpressed and totally uncoupled from cell cycle con-
trol in the transformed state. It is not likely that the high level of gp130 in
transformed cells is due simply to an increased proportion of replicating cells
(42) because the parent line and the SV40-transformed fibroblasts show similar
growth rates (27). Further studies are required to clarify the relationship
between gp130 expression and cell kinetics in normal and transformed cells and
to identify parallels between expression of gp130 and other cell cycle-regulated
gene products (e.g., p53).
TR provide cells with iron, an essential nutrient, and cell surface expression
of TR is a prerequisite for cell division. The expression pattern of this prolif-
eration-associated glycoprotein initially seemed to be similar to that of gP 130.
Comparing conditions involved in the regulation of the two glycoproteins, we
found significant differences between gp130 expression and TR expression,
indicating that these glycoproteins are controlled by different mechanisms.
We conclude that gp130 has characteristics of a gene product that may be
involved in the control of cell growth. Modulating gp130 expression by growth
factors, anti-gp130 antibodies (24, 43-45), and transfection with gp130 expres-
sion vectors (37, 46-48) provide approaches to exploring the role of gp130 in
normal and abnormal cell proliferation.
Summary
Two characteristics of cell surface molecules involved in the regulation of cell
proliferation are altered expression in relation to growth phase in normal cells
and overexpression in transformed cells. Here, we describe a similar pattern of
expression for a 130-kD cell surface glycoprotein (gp130) in human cells. Syn-
thesis and cell surface expression of gp130 were greatly increased in both virally
and chemically transformed fibroblasts, fibrosarcomas, a squamous cell carci-
noma of the skin, and T cell leukemia lines. Furthermore, gp130 expression was
induced in serum-starved fetal fibroblasts by serum stimulation, and in fresh T
cells by various activating agents. Expression in response to serum stimulation
was associated primarily with the transition from a quiescent state (Go) into the
cell cycle (G,).
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